

**AMENDMENTS TO THE CLAIMS:**

This listing of the claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A method for increasing an immune response in an animal, comprising administering a compound which binds to ~~a C-type lectin a protein with the amino acid sequence of SEQ ID NO: 2~~ on the surface of a dendritic cell, ~~with the proviso that the C-type lectin is not the DEC 205 receptor, wherein said compound is bound to an antigen.~~
2. (original) The method of claim 1 wherein said animal is a mammal.
3. (original) The method of claim 2 wherein said mammal is a human.
4. (canceled).
5. (currently amended) The method of claim [[4]] 1 wherein said antigen is bound to said compound by a) covalent binding, b) ligand-ligand interaction, c) complexing, d) ligation, or e) expression of a fusion protein comprising said antigen and said compound.
6. (currently amended) The method of claim [[4]] 1 wherein said antigen is a cancer antigen.
7. (original) The method of claim 6 wherein said method generates an immune response against tumor cells containing or expressing said cancer antigen.
8. (currently amended) The method of claim 1 wherein said compound is selected from the group consisting of a mannose carbohydrate, a fucose carbohydrate, ~~a plant lectin~~, an antibiotic, a sugar, a protein, and an antibody.
9. (withdrawn) The method of claim 8 wherein said mannose carbohydrate is mannan or D-mannose.
10. (withdrawn) The method of claim 8 wherein said fucose carbohydrate is L-fucose.
11. (withdrawn) The method of claim 8 wherein said plant lectin is concanavalin A.

12. (withdrawn) The method of claim 8 wherein said antibiotic is pradimicin A.

13. (withdrawn) The method of claim 8 wherein said sugar is selected from the group consisting of N-acetyl-D-glucosamine and galactose.

14. (withdrawn) The method of claim 8 wherein said protein is selected from the group consisting of gp120, analogs of gp120 and fragments of gp120.

Claims 15 – 17 (canceled).

18. (original) The method of claim 8 wherein said antibody is a monoclonal antibody.

Claims 19 – 21 (canceled).

22. (currently amended) The method of claim 8 wherein said antibody is selected from the group consisting of AZN-D1 and AZN-D2 i) an antibody produced by hybridoma ECACC accession number 99040818 and ii) an antibody produced by hybridoma ECACC accession number 99040819.

23. (currently amended) A method for generating an immune response against tumor cells in an animal, the method comprising administering a compound which binds to a C-type lectin a protein with the amino acid sequence of SEQ ID NO: 2 on the surface of the a dendritic cell, the compound having at least a portion of a cancer antigen attached thereto.